Aberrant overexpression of membrane-associated mucin contributes to tumor progression in adult T-cell leukemia/lymphoma cells

Leukemia and Lymphoma

Volumn 52, Issue 6, 2011, Pages 1108-1117

  Hasegawa, Hiroo ^a   Komoda, Minori ^a   Yamada, Yasuaki ^a   Yonezawa, Suguru ^b   Tsutsumida, Hideaki ^b   Nagai, Kazuhiro ^c   Atogami, Sunao ^a   Tsuruda, Kazuto ^a   Osaka, Akemi ^a   Sasaki, Daisuke ^a   Yanagihara, Katsunori ^a   Imaizumi, Yoshitaka ^a   Tsukasaki, Kunihiro ^a   Miyazaki, Yasushi ^a   Kamihira, Shimeru ^a  

^a NAGASAKI UNIVERSITY   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

^c NAGASAKI UNIVERSITY HOSPITAL   (Japan)

Author keywords

adhesion molecules; adult T cell leukemia lymphoma; apoptosis; MUC1

Indexed keywords

MESSENGER RNA; MUCIN 1; SMALL INTERFERING RNA;

ADULT; APOPTOSIS; ARTICLE; CELL ADHESION; CELL AGGREGATION; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; LEUKEMIA CELL; LYMPHOMA CELL; MAJOR CLINICAL STUDY; METASTASIS; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; T CELL LEUKEMIA; T CELL LYMPHOMA; TUMOR GROWTH;

ADULT; APOPTOSIS; CELL AGGREGATION; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE PROGRESSION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HL-60 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKEMIA-LYMPHOMA, ADULT T-CELL; MUCIN-1; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR MARKERS, BIOLOGICAL; U937 CELLS;

EID: 79957451102     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.559671     Document Type: Article

References (60)

1. Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 2004;4: 45-60. (Pubitemid 38082153)
2. Gendler SJ, Spicer AP, Lalani EN, et al. Structure and biology of a carcinoma-associated mucin, MUC1. Am Rev Respir Dis 1991;144:S42-S47.
3. Baldus SE, Engelmann K, Hanisch FG. MUC1 and the MUCs: a family of human mucins with impact in cancer biology. Crit Rev Clin Lab Sci 2004;41:189-231. (Pubitemid 38765096)
4. Spicer AP, Rowse GJ, Lidner TK, Gendler SJ. Delayed mammary tumor progression in Muc-1 null mice. J Biol Chem 1995;270:30093-30101. (Pubitemid 26001684)
5. Li Y, Liu D, Chen D, Kharbanda S, Kufe D. Human DF3/ MUC1 carcinoma-associated protein functions as an oncogene. Oncogene 2003;22:6107-6110. (Pubitemid 37175889)
6. Rakha EA, Boyce RW, Abd El-Rehim D, et al. Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Mod Pathol 2005;18:1295-1304. (Pubitemid 41348648)
7. Yonezawa S, Goto M, Yamada N, Higashi M, Nomoto M. Expression profiles of MUC1, MUC2, and MUC4 mucins in human neoplasms and their relationship with biological behavior. Proteomics 2008;8:3329-3341.
8. Brayman M, Thathiah A, Carson DD. MUC1: a multifunctional cell surface component of reproductive tissue epithelia. Reprod Biol Endocrinol 2004;2:4.
9. Carraway KL 3rd, Funes M, Workman HC, Sweeney C. Contribution of membrane mucins to tumor progression through modulation of cellular growth signaling pathways. Curr Top Dev Biol 2007;78:1-22.
10. Sloane JP, Hughes F, Ormerod MG. An assessment of the value of epithelial membrane antigen and other epithelial markers in solving diagnostic problems in tumour histopathology. Histochem J 1983;15:645-654. (Pubitemid 13011787)
11. Delsol G, Gatter KC, Stein H, et al. Human lymphoid cells express epithelial membrane antigen. Implications for diagnosis of human neoplasms. Lancet 1984;2:1124-1129. (Pubitemid 15210848)
12. Takahashi T, Makiguchi Y, Hinoda Y, et al. Expression of MUC1 on myeloma cells and induction of HLA-unrestricted CTL against MUC1 from a multiple myeloma patient. J Immunol 1994;153:2102-2109. (Pubitemid 24256681)
13. Treon SP, Raje N, Anderson KC. Immunotherapeutic strategies for the treatment of plasma cell malignancies. Semin Oncol 2000;27:598-613.
14. Singh R, Bandyopadhyay D. MUC1: a target molecule for cancer therapy. Cancer Biol Ther 2007;6:481-486. (Pubitemid 47328319)
15. Yamada Y, Tomonaga M, Fukuda H, et al. A new G-CSFsupported combination chemotherapy, LSG15, for adult Tcell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol 2001;113:375-382. (Pubitemid 32523141)
16. Tsukasaki K, Hermine O, Bazarbachi A, et al. Definition, prognostic factors, treatment, and response criteria of adult Tcell leukemia-lymphoma: a proposal from an international consensus meeting. J Clin Oncol 2009;27:453-459.
17. ShimoyamaM. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol 1991;79:428-437.
18. Karube K, Ohshima K, Tsuchiya T, et al. Expression of FoxP3, a key molecule in CD4CD25 regulatory T cells, in adult T-cell leukaemia/lymphoma cells. Br J Haematol 2004;126:81-84. (Pubitemid 38859486)
19. Kohno T, Yamada Y, Akamatsu N, et al. Possible origin of adult T-cell leukemia/lymphoma cells from human T lymphotropic virus type-1-infected regulatory T cells. Cancer Sci 2005;96:527-533. (Pubitemid 41387306)
20. Abe M, Uchihashi K, Kazuto T, et al. Foxp3 expression on normal and leukemic CD4CD25T cells implicated in human T-cell leukemia virus type-1 is inconsistent with Treg cells. Eur J Haematol 2008;81:209-217.
21. Uchiyama T. Human T cell leukemia virus type I (HTLV-I) and human diseases. Annu Rev Immunol 1997;15:15-37. (Pubitemid 27169273)
22. Dewan MZ, Terashima K, Taruishi M, et al. Rapid tumor formation of human T-cell leukemia virus type 1-infected cell lines in novel NOD-SCID/gammac(null) mice: suppression by an inhibitor against NF-kappaB. J Virol 2003;77:5286-5294. (Pubitemid 36460942)
23. Uchiyama T, Ishikawa T, Imura A. Cell adhesion molecules in HTLV-I infection. J Acquir Immune Defic Syndr Hum Retrovirol 1996;13(Suppl. 1):S114-S118.
24. Hasegawa H, Nomura T, Kishimoto K, Yanagisawa K, Fujita S. SFA-1/PETA-3 (CD151), a member of the transmembrane 4 superfamily, associates preferentially with alpha 5 beta 1 integrin and regulates adhesion of human T cell leukemia virus type 1-infected T cells to fibronectin. J Immunol 1998;161:3087-3095. (Pubitemid 28425736)
25. Sasaki H, Nishikata I, Shiraga T, et al. Overexpression of a cell adhesion molecule, TSLC1, as a possible molecular marker for acute-type adult T-cell leukemia. Blood 2005;105:1204-1213. (Pubitemid 40170895)
26. Hasegawa H, Yamada Y, Harasawa H, et al. Sensitivity of adult T-cell leukaemia lymphoma cells to tumour necrosis factor-related apoptosis-inducing ligand. Br J Haematol 2005;128:253-265.
27. Yamada Y, Ohmoto Y, Hata T, et al. Features of the cytokines secreted by adult T cell leukemia (ATL) cells. Leuk Lymphoma 1996;21:443-447. (Pubitemid 26144768)
28. Yamada Y, Sugawara K, Hata T, et al. Interleukin-15 (IL-15) can replace the IL-2 signal in IL-2-dependent adult T-cell leukemia (ATL) cell lines: expression of IL-15 receptor alpha on ATL cells. Blood 1998;91:4265-4272. (Pubitemid 28261991)
29. Maeda T, Yamada Y, Moriuchi R, et al. Fas gene mutation in the progression of adult T cell leukemia. J Exp Med 1999;189:1063-1071. (Pubitemid 29169823)
30. Hasegawa H, Yamada Y, Komiyama K, et al. Dihydroflavonol BB-1, an extract of natural plant Blumea balsamifera, abrogates TRAIL resistance in leukemia cells. Blood 2006;107: 679-688. (Pubitemid 43076394)
31. Hasegawa H, Yamada Y, Iha H, et al. Activation of p53 by Nutlin-3a, an antagonist of MDM2, induces apoptosis and cellular senescence in adult T-cell leukemia cells. Leukemia 2009;23:2090-2101.
32. de Cremoux P, Extra JM, Denis MG, et al. Detection of MUC1-expressing mammary carcinoma cells in the peripheral blood of breast cancer patients by real-time polymerase chain reaction. Clin Cancer Res 2000;6:3117-3122. (Pubitemid 30637736)
33. Utsunomiya T, Yonezawa S, Sakamoto H, et al. Expression of MUC1 and MUC2 mucins in gastric carcinomas: its relationship with the prognosis of the patients. Clin Cancer Res 1998;4:2605-2614. (Pubitemid 28523486)
34. Price MR, Rye PD, Petrakou E, et al. Summary report on the ISOBM TD-4 Workshop: analysis of 56 monoclonal antibodies against the MUC1 mucin. San Diego, Calif., November 17-23, 1996. Tumour Biol 1998;19(Suppl. 1):1-20. (Pubitemid 128707598)
35. Fattorossi A, Battaglia A, Malinconico P, et al. Constitutive and inducible expression of the epithelial antigen MUC1 (CD227) in human T cells. Exp Cell Res 2002;280:107-118. (Pubitemid 35230372)
36. Rahn JJ, Dabbagh L, Pasdar M, Hugh JC. The importance of MUC1 cellular localization in patients with breast carcinoma: an immunohistologic study of 71 patients and review of the literature. Cancer 2001;91:1973-1982. (Pubitemid 32476360)
37. Sagara M, Yonezawa S, Nagata K, et al. Expression of mucin 1 (MUC1) in esophageal squamous-cell carcinoma: its relationship with prognosis. Int J Cancer 1999;84:251-257. (Pubitemid 29256750)
38. Baldus SE, Hanisch FG, Kotlarek GM, et al. Coexpression of MUC1 mucin peptide core and the Thomsen-Friedenreich antigen in colorectal neoplasms. Cancer 1998;82:1019-1027. (Pubitemid 28136513)
39. Giatromanolaki A, Koukourakis MI, Sivridis E, et al. Coexpression of MUC1 glycoprotein with multiple angiogenic factors in non-small cell lung cancer suggests coactivation of angiogenic and migration pathways. Clin Cancer Res 2000;6:1917-1921. (Pubitemid 30305090)
40. Tsutsumida H, Goto M, Kitajima S, Kubota I, Hirotsu Y, Yonezawa S. Combined status of MUC1 mucin and surfactant apoprotein A expression can predict the outcome of patients with small-size lung adenocarcinoma. Histopathology 2004;44:147-155. (Pubitemid 38296974)
41. Ligtenberg MJ, Buijs F, Vos HL, Hilkens J. Suppression of cellular aggregation by high levels of episialin. Cancer Res 1992;52:2318-2324.
42. Ren J, Agata N, Chen D, et al. Human MUC1 carcinomaassociated protein confers resistance to genotoxic anticancer agents. Cancer Cell 2004;5:163-175. (Pubitemid 38283802)
43. Treon SP, Mollick JA, Urashima M, et al. Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone. Blood 1999;93:1287-1298. (Pubitemid 29076144)
44. Dyomin VG, Palanisamy N, Lloyd KO, et al. MUC1 is activated in a B-cell lymphoma by the t(1;14)(q21;q32;translocation and is rearranged and amplified in B-cell lymphoma subsets. Blood 2000;95:2666-2671. (Pubitemid 30210548)
45. Delsol G, Al Saati T, Gatter KC, et al. Coexpression of epithelial membrane antigen (EMA), Ki-1, and interleukin-2 receptor by anaplastic large cell lymphomas. Diagnostic value in so-called malignant histiocytosis. Am J Pathol 1988;130:59-70. (Pubitemid 18044833)
46. Brossart P, Schneider A, Dill P, et al. The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. Cancer Res 2001;61:6846-6850. (Pubitemid 32896509)
47. Brugger W, Buhring HJ, Grunebach F, et al. Expression of MUC-1 epitopes on normal bone marrow: implications for the detection of micrometastatic tumor cells. J Clin Oncol 1999;17:1535-1544. (Pubitemid 29220862)
48. Dent GA, Civalier CJ, Brecher ME, Bentley SA. MUC1 expression in hematopoietic tissues. Am J Clin Pathol 1999; 111:741-747. (Pubitemid 29250102)
49. Rughetti A, Biffoni M, Pierelli L, et al. Regulated expression of MUC1 epithelial antigen in erythropoiesis. Br J Haematol 2003;120:344-352. (Pubitemid 36194188)
50. Correa I, Plunkett T, Vlad A, et al. Form and pattern of MUC1 expression on T cells activated in vivo or in vitro suggests a function in T-cell migration. Immunology 2003; 108:32-41. (Pubitemid 36110862)
51. Osaka A, Yanagihara K, Yamada Y, et al. Elevation of serum KL-6 glycoprotein or surfactant protein-D in adult T-cell leukemia with distinct pulmonary complications. Tohoku J Exp Med 2009;218:99-105.
52. Theodoropoulos G, Carraway KL. Molecular signaling in the regulation of mucins. J Cell Biochem 2007;102:1103-1116. (Pubitemid 350220032)
53. Kam JL, Regimbald LH, Hilgers JH, et al. MUC1 synthetic peptide inhibition of intercellular adhesion molecule-1 and MUC1 binding requires six tandem repeats. Cancer Res 1998;58:5577-5581. (Pubitemid 28551148)
54. McDermott KM, Crocker PR, Harris A, et al. Overexpression of MUC1 reconfigures the binding properties of tumor cells. Int J Cancer 2001;94:783-791. (Pubitemid 33032824)
55. Galiegue-Zouitina S, Delestre L, Dupont C, Troussard, Shelley CS. Underexpression of RhoH in hairy cell leukemia. Cancer Res 2008;68:4531-4540.
56. Li Y, Kuwahara H, Ren J, Wen G, Kufe D. The c-Src tyrosine kinase regulates signaling of the human DF3/MUC1 carcinoma- associated antigen with GSK3 beta and beta-catenin. J Biol Chem 2001;276:6061-6064.
57. Kufe D. Oncogenic function of the MUC1 receptor subunit in gene regulation. Oncogene 2010;29:5663-5666.
58. Bafna S, Kaur S, Batra SK. Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells. Oncogene 2010;29:2893-2904.
59. Wei X, Xu H, Kufe D. Human MUC1 oncoprotein regulates p53-responsive gene transcription in the genotoxic stress response. Cancer Cell 2005;7:167-178. (Pubitemid 40248342)
60. Smyth MJ, Takeda K, Hayakawa Y, Peschon JJ, van den Brink MR, Yagita H. Natures TRAIL-on a path to cancer immunotherapy. Immunity 2003;18:1-6. (Pubitemid 36120682)